A New Dawn in Eosinophilic Esophagitis Treatment: TEZSPIRE® Shines in Phase 3 Trial

Breaking News: Amgen and AstraZeneca Announce Positive Phase 3 Results for TEZSPIRE® in Eosinophilic Esophagitis

Today marks a pivotal moment for the over 470,000 individuals living with Eosinophilic Esophagitis (EoE) in the U.S.. Amgen and AstraZeneca have jointly announced compelling positive top-line results from their Phase 3 CROSSING trial, demonstrating that TEZSPIRE® (tezepelumab-ekko) achieved statistically significant and clinically meaningful improvements in both disease pathology and symptoms of this challenging chronic inflammatory condition. These groundbreaking findings, sustained over 52 weeks, offer a beacon of hope for a patient population often struggling with inadequate disease control from existing therapies.

What is Eosinophilic Esophagitis (EoE)?

Eosinophilic Esophagitis (EoE) is a chronic, immune-mediated inflammatory disorder of the esophagus, characterized by the accumulation of a specific type of white blood cell, eosinophils, in the esophageal lining. This buildup leads to inflammation and dysfunction of the esophagus, often resulting in severe swallowing difficulties and other debilitating symptoms.

EoE is a progressive condition that, if not adequately treated, can lead to serious complications such as food impaction (food getting stuck in the throat) and esophageal narrowing. The prevalence of EoE has seen a dramatic increase, rising five-fold in the U.S. since 2009. As of 2025, the U.S. alone accounted for approximately 512,000 diagnosed prevalent cases of EoE, with global pooled prevalence estimated at around 40.04 cases per 100,000 inhabitant-years between 1976 and 2022. Males are predominantly affected, comprising roughly 65% of patients. The disease significantly impacts patients' quality of life, extending beyond physical discomfort to affect mental health, emotional well-being, and social interactions.

The Burden of EoE: A Growing Concern

The rise in EoE prevalence underscores an urgent unmet need for more effective treatment options. Current first-line treatments, which include dietary restrictions, swallowed topical corticosteroids, and proton pump inhibitors (PPIs), often fall short, leaving nearly half of patients, including adolescents, without adequate disease control. The continuous struggle with symptoms like dysphagia can make daily meals stressful and challenging, leading to reduced quality of life.

What is TEZSPIRE® (Tezepelumab)?

TEZSPIRE® (tezepelumab-ekko) is a first-in-class human monoclonal antibody that targets and blocks thymic stromal lymphopoietin (TSLP), a key epithelial cytokine located at the top of multiple inflammatory cascades. By inhibiting TSLP, TEZSPIRE® aims to prevent the release of pro-inflammatory cytokines and dampen the immune response associated with various epithelial-driven inflammatory diseases, including severe asthma and chronic rhinosinusitis with nasal polyps, for which it is already approved.

This unique mechanism of action positions TEZSPIRE® as a promising therapeutic option that addresses the fundamental drivers of inflammation in conditions like EoE. In October 2021, tezepelumab was granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of EoE, acknowledging the significant need for new therapies for this rare disease.

The Landmark Phase 3 CROSSING Trial Results: What Do They Mean for EoE Patients?

The positive results from the Phase 3 CROSSING trial are a significant advancement for the EoE community. The randomized, double-blind, placebo-controlled, multi-center trial evaluated the efficacy and safety of TEZSPIRE® administered subcutaneously every four weeks in adults and adolescents (aged 12-80 years) with symptomatic and histologically active EoE. A total of 368 patients were enrolled and randomized to receive either a low or high dose of TEZSPIRE® or placebo. Patients in the trial were permitted to continue background medications for EoE, such as proton pump inhibitors and swallowed topical corticosteroids, provided their dosage was stable.

The trial met both of its co-primary endpoints at week 24, with improvements sustained through week 52.

Key Findings from the CROSSING Trial (Week 24 and 52):

"We're pleased that TEZSPIRE® showed efficacy in a third epithelial-driven inflammatory condition, eosinophilic esophagitis," stated Jay Bradner, M.D., executive vice president of Research and Development, Artificial Intelligence and Data at Amgen, on August 27, 2026. "In this Phase 3 trial, TEZSPIRE® improved both the underlying inflammation and the swallowing difficulties that can make eosinophilic esophagitis so disruptive for patients. That combination is important for patients and builds confidence in TEZSPIRE® as a potential new treatment for people struggling with EoE".

Sharon Barr, Executive Vice President, BioPharmaceuticals R&D at AstraZeneca, echoed this sentiment, noting, "The positive results of the Phase III CROSSING trial reinforce our confidence in the differentiated mechanism of action of Tezspire, which has now demonstrated clinically meaningful efficacy in a third epithelial-driven inflammatory disease. Epithelial science represents an important and rapidly evolving area in respiratory and immunology medicine, and we look to sharing these results at an upcoming medical meeting and with regulatory authorities as quickly as possible".

Arjan Bredenoord, MD, Gastroenterologist and professor at the Amsterdam University Medical Center, Amsterdam, The Netherlands, and a primary investigator in the trial, highlighted the significance of these sustained improvements: "The impressive results from the CROSSING trial sustained over 52 weeks demonstrate that tezepelumab, taken every four weeks, could provide a new approach to treating EoE, with the potential to help more patients achieve remission and symptom improvement".

How Does TEZSPIRE® Work in EoE?

TEZSPIRE®’s unique mechanism of action targets thymic stromal lymphopoietin (TSLP), a cytokine produced by the epithelial cells lining the esophagus. TSLP acts as an "alarmin" at the top of the inflammatory cascade, initiating and amplifying the immune response that drives various allergic and inflammatory diseases, including EoE. In EoE, this pathway contributes to the recruitment and activation of eosinophils and other inflammatory cells in the esophageal tissue.

By blocking TSLP, TEZSPIRE® aims to interrupt this inflammatory pathway at its source, preventing the downstream release of various pro-inflammatory mediators and subsequent tissue damage. This upstream intervention is believed to be crucial for achieving both histologic remission and symptomatic improvement in EoE, addressing not just the symptoms but also the underlying inflammation. The safety profile observed in the CROSSING trial was consistent with TEZSPIRE®'s established profile in its other approved indications.

The Patient Perspective: Impact and Hope

For patients living with EoE, the positive results of the CROSSING trial offer substantial hope for a future with better disease management and an improved quality of life. The chronic nature of EoE and its symptoms, particularly difficulty swallowing (dysphagia), can profoundly affect daily activities, mealtime enjoyment, and social interactions. Studies have shown that EoE significantly impacts patients' emotional health (35%) and social life (34%), with many experiencing anxiety and depression.

The ability of TEZSPIRE® to address both the underlying inflammation (histologic remission) and the most bothersome symptom (dysphagia) is critical for improving patient outcomes. With nearly half of patients currently not achieving adequate disease control, a new therapeutic option that targets the root cause of the inflammation could transform the treatment landscape and offer renewed hope for a life less constrained by EoE.

The Road Ahead: Regulatory Review and Future Implications

With these compelling Phase 3 results now in hand, Amgen and AstraZeneca plan to engage with regulatory authorities to seek approval for TEZSPIRE® in eosinophilic esophagitis. Full trial data will also be shared with the scientific community at an upcoming medical meeting.

If approved, TEZSPIRE® would represent a significant new treatment option, offering a mechanism of action distinct from currently available therapies. This could provide clinicians and patients with a valuable tool in the personalized management of EoE, especially for those who do not respond adequately to existing treatments. The development of targeted drug therapies like TEZSPIRE® is crucial for addressing the increasing burden of EoE and improving long-term outcomes for affected individuals worldwide.

Frequently Asked Questions

What are the main symptoms of Eosinophilic Esophagitis (EoE)?

The primary symptoms of Eosinophilic Esophagitis (EoE) often revolve around esophageal dysfunction due to inflammation. These commonly include difficulty swallowing (dysphagia), food impaction where food gets stuck in the throat, chest pain, and abdominal pain. Children may also experience feeding difficulties, poor growth, and vomiting. The symptoms can significantly impact daily life, especially mealtimes, leading to stress and anxiety.

How does TEZSPIRE® differ from current EoE treatments?

TEZSPIRE® (tezepelumab-ekko) stands apart from most current EoE treatments, which primarily include dietary restrictions, proton pump inhibitors (PPIs), and swallowed topical corticosteroids. While Dupilumab is also approved, TEZSPIRE® is a first-in-class human monoclonal antibody that targets thymic stromal lymphopoietin (TSLP), a cytokine at the top of the inflammatory cascade. This upstream targeting mechanism offers a distinct approach to reducing the underlying eosinophilic inflammation and improving swallowing difficulties, providing a novel therapeutic pathway for patients.

When might TEZSPIRE® be available for EoE patients?

Following the positive Phase 3 CROSSING trial results announced on August 27, 2026, Amgen and AstraZeneca will now compile and submit the full data to regulatory authorities for review. The exact timeline for potential approval and availability of TEZSPIRE® for Eosinophilic Esophagitis will depend on the regulatory review process in various regions. Given its Orphan Drug Designation from October 2021, the review process might be expedited, but patients should consult their healthcare providers for the most up-to-date information.

Featured image by Murad Swaleh on Unsplash